Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Acquire Molecular Dx Test Maker Artus for $39.2M

NEW YORK, May 31 (GenomeWeb News) - Qiagen will acquire Artus of Germany, a maker of PCR-based diagnostic tests, for approximately $39.2 million in cash, the company said today.


Artus, located in Hamburg, focuses on diagnostic tests based on PCR and RT-PCR for infectious disease detection, pharmacogenomics, and veterinary diagnostics. The company, founded in 1998 as a spin-off from the Bernhard-Nocht-Institute for Tropical Medicine in Hamburg, sells more than 60 assays to detect viral and bacterial pathogens and has distribution agreements with Abbott Laboratories and MWG Biotech.


Qiagen said in a statement that "this acquisition is a perfect fit in its strategy to increase Qiagen's value as a partner to the molecular diagnostics industry." The company expects the acquisition will add about $15 million in net sales and $1.5 million to $2 million in net income to its 2006 earnings.


Qiagen reported $380.6 million in revenues for its 2004 fiscal year.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.